Detalhe da pesquisa
1.
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
Invest New Drugs
; 40(3): 586-595, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35113285